Breaking News Instant updates and real-time market news.

CELG

Celgene

$119.64

0.88 (0.74%)

, MDCO

The Medicines Co.

$36.23

0.71 (2.00%)

10:25
01/09/17
01/09
10:25
01/09/17
10:25

JPMorgan to hold a conference

35th Annual Healthcare Conference is being held in San Francisco on January 9-12 with webcasted company presentations to begin on January 9 at 10:30 am; not all company presentations may be webcasted. Webcast Link

CELG

Celgene

$119.64

0.88 (0.74%)

MDCO

The Medicines Co.

$36.23

0.71 (2.00%)

MNK

Mallinckrodt

$53.14

0.39 (0.74%)

HCA

HCA Holdings

$78.94

2.315 (3.02%)

EW

Edwards Lifesciences

$98.09

1.0164 (1.05%)

BRKR

Bruker

$22.04

0.19 (0.87%)

ALXN

Alexion

$143.61

4.43 (3.18%)

BMRN

BioMarin

$86.85

0.56 (0.65%)

WAT

Waters

$138.97

-1.01 (-0.72%)

MOH

Molina Healthcare

$56.74

-0.35 (-0.61%)

VRTX

Vertex

$79.39

0.33 (0.42%)

MDT

Medtronic

$73.70

0.83 (1.14%)

IONS

Ionis Pharmaceuticals

$47.83

0.74 (1.57%)

HMSY

HMS Holdings

$18.09

-0.31 (-1.68%)

RDUS

Radius Health

$42.44

1.69 (4.15%)

ACOR

Acorda Therapeutics

$21.15

0.4 (1.93%)

IRWD

Ironwood

$15.85

0.42 (2.72%)

AGN

Allergan

$220.62

1.54 (0.70%)

ASND

Ascendis Pharma

$20.68

0.01 (0.05%)

NUVA

NuVasive

$67.14

0.37 (0.55%)

SCAI

Surgical Care Affiliates

$48.75

1.7 (3.61%)

NH

NantHealth

$10.56

0.29 (2.82%)

ARIA

ARIAD

$13.74

0.34 (2.54%)

BIIB

Biogen

$295.00

1.43 (0.49%)

  • 09

    Jan

  • 09

    Jan

  • 09

    Jan

  • 11

    Jan

  • 11

    Jan

  • 19

    Jan

  • 25

    Jan

  • 26

    Jan

  • 26

    Jan

  • 28

    Jan

  • 01

    Feb

  • 12

    Feb

  • 21

    Feb

  • 24

    Feb

  • 30

    Mar

  • 27

    Apr

  • 29

    Apr

CELG Celgene
$119.64

0.88 (0.74%)

01/05/17
RHCO
01/05/17
NO CHANGE
RHCO
Celgene likely to deliver beat and raise results, says SunTrust
SunTrust analyst Yatin Suneja expects Celgene to deliver beat and raise Q4 result, driven primarily by the company's hematology franchise. Partly due to Otezla's increased foreign sales and Revlimid's continued strong trends, Suneja expects Celgene to raise its 2017 guidance above Street estimates. The analyst reiterates a $149 price target and a Buy rating on the shares.
01/05/17
JEFF
01/05/17
NO CHANGE
JEFF
Celgene, Alkermes among Jefferies' top 2017 Biotech picks
Jefferies' Biotechnology equity research team laid out their top picks for 2017. Following a volatile two years, the biotech space seeks to achieve "greater equilibrium" in 2017, the analysts write in a research note. They cite increasing competition, slowing volumes, and ramping payer leverage as reasons to remain selective when picking stocks this year and beyond. Among large-caps, Jefferies likes Celgene (CELG) for its "best-in-class growth" and sees limited downside in Gilead (GILD) shares. In the mid-cap space, the firm favors Alkermes (ALKS) given the prospects for Vivitrol and Aristada and a "strong" neurology pipeline as well as Vertex (VRTX). Jefferies' top small-cap picks include Aevi Genomics Medicine, Alder Biopharmaceuticals (ALDR), AMAG Pharmaceuticals (AMAG), DBV Technologies (DBVT), Immunomedics (IMMU), Ignyta (RXDX), Karyopharm (KPTI), RA Pharmaceuticals (RARX), TherapeuticsMD (TXMD) and Xenon Pharmaceuticals (XENE).
12/20/16
FBCO
12/20/16
NO CHANGE
FBCO
Outperform
Celgene added to the US Focus List at Credit Suisse
Credit Suisse added Celgene to the US Focus List and maintained its Outperform rating and $145 price target. The firm said could update expectations for their outlook in early January, and if biotech starts to recover sometime in 2017, they think generalists will favor Celgene growth profile compared to its large cap peers. The firm's analyst continues to favor Celgene given its best top and bottom line profile of its large cap peers and said it has one of the most diversified pipelines.
12/01/16
WBLR
12/01/16
NO CHANGE
WBLR
Celgene, Zoetis among top healthcare picks at William Blair
William Blair analysts named their top health care picks for 2017, identifying Evolent Health (EVH) as their top HC Services and HC IT pick, Zoetis (ZTS) as their top dental and animal health pick,and Pacific Biosciences (PACB) as their top diagnostic services and life sciences choice, The firm identified ARIAD (ARIA), Celgene (CELG) and SAGE Therapeutics (SAGE) as their top biotech choices. It named Edwards Lifesciences (EW), Nevro (NVRO), and K2M Group (KTWO) as its favorite med tech picks.
MDCO The Medicines Co.
$36.23

0.71 (2.00%)

12/05/16
12/05/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HP Enterprise (HPE) initiated with a Buy at Gabelli. 2. Goldman Sachs (GS) was initiated with a Buy at HSBC while Morgan Stanley (MS) initiated with a Hold. 3. Williams (WMB) reinstated with an Overweight at Barclays. 4. Sherwin-Williams (SHW) initiated with an Underperform at BofA/Merrill. 5. The Medicines Co. (MDCO) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/16
HCWC
12/05/16
INITIATION
Target $57
HCWC
Buy
The Medicines Co. initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started The Medicines Company with a Buy rating and $57 price target. The analyst views the Phase 3-ready inclisiran as the company's most valuable asset.
11/16/16
NEED
11/16/16
NO CHANGE
Target $98
NEED
Buy
Alnylam price target lowered to $98 from $137 at Needham
Needham analyst Alan Carr lowered his price target for Alnylam (ALNY) to $98 from $137 after the company announced that collaborator Sanofi (SNY) exercised its option to co-develop and co-commercialize fitusiran, with the analyst adjusting his models to reflect Sanofi taking greater share of revenue. He also notes that Alnylam's collaborator The Medicines Co. (MDCO) announced positive Phase 2 PCSK9 results. Carr reiterates a Buy rating on Alnylam's shares.
01/06/17
JEFF
01/06/17
NO CHANGE
Target $49
JEFF
Buy
Amgen ruling could mean 'blue skies' for Medicines Co., says Jefferies
Jefferies analyst Biren Amin raised his price target for The Medicines Co. (MDCO) to $49 from $43 after the District Court of Delaware ruled in favor of Amgen (AMGN) on the permanent injunction against Sanofi (SNY) and Regeneron's (RENG) Praluent. The ruling should have a favorable read-through to Medicines' inclisiran since the drug is "completely unique to the monoclonal antibody approach" and therefore would not infringe on Amgen's patents, Amin tells investors in a research note titled "Injunction on Sanofi/REGN's Praluent Could Mean Blue Skies for Inclisiran." The analyst raised his inclisiran peak sales estimates to $2.4B in 2027 and keeps a Buy rating on Medicines shares. The stock is up $2.98, or 8%, to $38.50 in pre-market trading.
MNK Mallinckrodt
$53.14

0.39 (0.74%)

11/21/16
UBSW
11/21/16
NO CHANGE
Target $92
UBSW
Buy
Mallinckrodt weakness does not make sense, says UBS
UBS analyst Marc Goodman attended Mallinckrodt investors meetings and came away believing investors misunderstand the company story. The analyst said the company's Acthar drug, which has come under fire, has little relevance to the overall story. Goodman said the company has focused on enhancing clinical and health-economics data to help support better coverage and it is working. He said its emerging pipeline is under-appreciated. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
11/30/16
LEER
11/30/16
NO CHANGE
Target $70
LEER
Outperform
Mallinckrodt price target lowered to $70 from $92 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Mallinckrodt to $70 from $92 following quarterly results due to a lack of near-term catalysts. The analyst reiterates an Outperform rating on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
12/07/16
OPCO
12/07/16
INITIATION
Target $72
OPCO
Outperform
Mallinckrodt assumed with an Outperform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of Mallinckrodt with an Outperform rating but lowered his price target for the shares to $72 from $115. He views Acthar as a "durable growth asset" and believes Mallinckrodt remains well positioned to drive mid-to-high single-digit top line growth from the company's specialty brand segment.
HCA HCA Holdings
$78.94

2.315 (3.02%)

11/09/16
MZHO
11/09/16
DOWNGRADE
Target $78
MZHO
Neutral
HCA Holdings downgraded to Neutral on Republican win at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded HCA Holdings to Neutral from Buy citing Donald Trump's election and the move to a GOP Congress. Following the election results, Skolnick sees an "extreme risk" for the ACA to be repealed and replaced and for the loss of the Medicaid expansion, both of which she notes have been primary drivers of results for hospitals and health plans. She cut her price target on the stock to $78 from $97.
11/09/16
AVON
11/09/16
DOWNGRADE
AVON
Market Perform
HCA Holdings downgraded to Market Perform from Outperform at Avondale
11/15/16
UBSW
11/15/16
NO CHANGE
Target $90
UBSW
Buy
HCA Holdings share buybacks a strong positive signal, says UBS
UBS analyst A.J. Rice said HCA sent a strong positive signal with its authorization of an additional share repurchase program for up to $2B and he recommends focusing on HCA within the Hospital group while waiting for clarity on ACA in the wake of the election. Rice, who citing HCA's margins, above average growth, cash flow, share repurchases and below average exposure to ACA, keeps a Buy rating and $90 price target on the stock.
01/03/17
PIPR
01/03/17
INITIATION
Target $81
PIPR
Overweight
HCA Holdings initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Sarah James initiated HCA Holdings with an Overweight and an $81 price target.
EW Edwards Lifesciences
$98.09

1.0164 (1.05%)

12/07/16
COWN
12/07/16
NO CHANGE
Target $120
COWN
Outperform
Edwards Lifesciences price target lowered to $120 from $130 at Cowen
Cowen analyst Joshua Jennings lowered his price target on Edwards Lifesciences to $120 from $130 ahead of tomorrow's investor day. The analyst expects it to be neutral but said the company's purchasing data puts it on track to meet the Street's Q4 growth forecast. He also sees investor sentiment improving in 2017, leaving room for upside. Jennings maintained his Outperform rating on Edwards Lifesciences shares.
12/09/16
LEER
12/09/16
NO CHANGE
Target $110
LEER
Outperform
Edwards Lifesciences price target lowered to $110 from $130 at Leerink
Leerink analyst Danielle Antalffy lowered her price target for Edwards Lifesciences to $110 from $130 to reflect a recent multiple pullback across MedTech. The analyst believes the company's 2017 guidance will prove to be a "base-case" scenario, and has a high level of confidence that Edwards Lifesciences is well-positioned for outperformance throughout the year. She reiterates an Outperform rating on the shares.
01/03/17
GUGG
01/03/17
UPGRADE
GUGG
Buy
Edwards Lifesciences upgraded to Buy from Neutral at Guggenheim
01/03/17
JPMS
01/03/17
NO CHANGE
JPMS
JPMorgan predicts more challenging 2017 for MedTechs
JPMorgan laid out its top picks for 2017 in the Medical Technology space despite predicting a "challenging" year for the sector. A rising interest rate and rising dollar environment, combined with lower top-line growth on tough first half comparisons, are likely to make 2017 outperformance harder to come by, the firm earlier today in a research note. JPMorgan believes the headwinds could change into the second half of 2017, however. Among large-caps, the firm likes Boston Scientific (BSX) and Edwards Lifesciences (EW). Among small-caps, the firm's top picks are iRhythm Technologies (IRTC) and Nevro (NVRO).
BRKR Bruker
$22.04

0.19 (0.87%)

01/04/17
LEHM
01/04/17
DOWNGRADE
Target $22
LEHM
Equal Weight
Bruker downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Jack Meehan downgraded Bruker (BRKR) to Equal Weight citing a more cautious outlook on the company's European academic exposure. He lowered his price target for the shares to $22 from $30. Meehan this morning lowered his Life Science Tools & Diagnostics sector view to Neutral from Positive as he sees a more balanced set-up in the near-term. The analyst coupled the downgrade of Bruker with an upgrade of Agilent (A).
11/10/16
LEER
11/10/16
INITIATION
Target $21
LEER
Market Perform
Bruker resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Bruker with a Market Perform rating and $21 price target.
12/14/16
JPMS
12/14/16
DOWNGRADE
Target $20
JPMS
Underweight
Bruker downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Bruker to Underweight citing the company's below average growth rate and questions surrounding its ability to expand margins. The analyst lowered his price target for the shares to $20 from $23.
12/14/16
JPMS
12/14/16
DOWNGRADE
Target $6
JPMS
Neutral
Accuray downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accuray (ARAY) to Neutral citing a "sluggish" end market and the company's ongoing operational challenges. Accuray has not demonstrated consistent order growth or the ability to drive market share, Peterson tells investors in a research note. He lowered his price target for the shares to $6 from $8. The analyst's top picks in the Life Sciences space for 2017 are Agilent (A) and Thermo Fisher (TMO). Peterson this morning also downgraded Bruker (BRKR) to Underweight,
ALXN Alexion
$143.61

4.43 (3.18%)

12/22/16
JEFF
12/22/16
NO CHANGE
Target $120
JEFF
Hold
Alexion failure adds to cautious sentiment, says Jefferies
Jefferies analyst Eun Yang says that while the Phase 3 study failure of Alexion's Soliris for prevention of delayed graft function after deceased donor kidney transplant is not meaningful to the valuation, it adds to the cautious sentiment on the shares. The analyst viewed trial as risky with a small market potential and did not include the indication in her estimates. She keeps a Hold rating on Alexion Pharmaceuticals with a $120 price target.
12/22/16
LEER
12/22/16
NO CHANGE
LEER
Outperform
Alexion Soliris forecasts not materially impacted by study failure, says Leerink
Leerink analyst Geoffrey Porges says the failure of Alexion's Soliris for the prevention of delayed graft function after kidney transplantation does not materially impact his long-term Soliris forecasts or growth rate, but does represent another example of Alexion ploughing Soliris profits into high risk trials for low value indications. The analyst reiterates an Outperform rating on the shares.
01/05/17
BOFA
01/05/17
INITIATION
Target $182
BOFA
Buy
Alexion coverage resumed with a Buy at BofA/Merrill
BofA/Merrill resumed coverage on Alexion with a Buy and a $182 price target following completion of the investigation saying historical financial statements and earnings will not need to be reinstated and 2016 guidance was reaffirmed.
01/05/17
SBSH
01/05/17
NO CHANGE
Target $173
SBSH
Buy
Citi calls Alexion 'high conviction' buy idea for 2017
Citi analyst Robyn Karnauskas calls Alexion Pharmaceuticals a "high conviction" buy idea for 2017 after the company disclosed its quarterly filing for Q3 with no restatement. The analyst is "encouraged" by the audit committee's findings and believes an overhang is now lifted. Karnauskas thinks consensus 2017 numbers for Soliris are achievable and keeps a Buy rating on Alexion with a $173 price target.
BMRN BioMarin
$86.85

0.56 (0.65%)

01/09/17
BMOC
01/09/17
NO CHANGE
BMOC
BioMarin shares likely to rise today, says BMO Capital
BMO Capital analyst M. Ian Somaiya expects BioMarin's stock to rise after the company reported updated Phase 1b/2 results of a trial of its hemophilia product BMN 270. The analyst notes that six of the seven patients taking the highest dose of the drug had a 91% reduction in ABR, a 98% reduction in prophylactic infusions and factor VIII levels that were in a normal range. The analyst says that the data should eliminate worries about the need for steroid prophylaxis for patients taking BMN 270. He keeps a $115 price target and an Outperform rating on the shares.
12/08/16
GABE
12/08/16
INITIATION
Target $109
GABE
Buy
BioMarin initiated with a Buy at Gabelli
Gabelli analyst Jing He initiated BioMarin with a Buy and a $109 price target saying it has the best orphan drug portfolio in the sector and that its sales could reach $2.2 billion by 2020.
12/08/16
12/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) coverage assumed with an Overweight at Morgan Stanley. 2. BioMarin (BMRN) initiated with a Buy at Gabelli. 3. Costco (COST) initiated with an Outperform at Credit Suisse. 4. Expedia (EXPE) initiated with an Outperform at CLSA while TripAdvisor (TRIP) was initiated with an Underperform. 5. Cree (CREE) initiated with an Outperform at JMP Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/09/16
COWN
12/09/16
NO CHANGE
Target $150
COWN
Outperform
BioMarin a top pick for 2017, says Cowen
Cowen analyst Phil Nadeau called BioMarin a top pick for 2017, citing its expected launch of two new products over the next 12-18 months, expectations for two additional programs to advance into pivotal trials, and for the company to break into non-GAAP profitability. Nadeau reiterated his Outperform rating and $150 price target on BioMarin shares.
WAT Waters
$138.97

-1.01 (-0.72%)

11/10/16
LEER
11/10/16
INITIATION
Target $163
LEER
Outperform
Waters resumed with an Outperform at Leerink
Leerink analyst Puneet Souda resumed coverage of Waters with an Outperform rating and $163 price target.
10/26/16
COWN
10/26/16
NO CHANGE
Target $147
COWN
Outperform
Waters price target lowered to $147 from $160 at Cowen
Cowen analyst Doug Schenkel lowered his price target on Waters to $147 from $160 as Q3 results were below expectations. The analyst feels pharma should grow enough to support margin expansion, providing a floor on earnings and limited downside on the shares. Schenkel maintained his Outperform rating on Waters shares.
01/06/17
WBLR
01/06/17
UPGRADE
WBLR
Outperform
Waters upgraded to Outperform from Market Perform at William Blair
William Blair analyst Amanda Murphy upgraded Waters Corporation to Outperform saying the recent pullback in shares provides a buying opportunity.
12/06/16
AVON
12/06/16
NO CHANGE
AVON
Outperform
Waters added to Conviction Buy List at Avondale
MOH Molina Healthcare
$56.74

-0.35 (-0.61%)

12/13/16
12/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CBS (CBS) upgraded to Outperform from Market Perform by BMO Capital analyst Daniel Salmon after Viacom (VIA) announced that it was no longer pursuing a merger. 2. Goldman analyst Matthew Borsch upgraded Molina Healthcare (MOH) to Buy and raised its price target to $65 from $59 citing attractive valuation and believes 2017 results will be more stable and stronger than expectations, particularly if ACA Medicaid coverage is maintained. 3. Janney Capital analyst Tyler Batory upgraded SeaWorld (SEAS) to Buy from Neutral based on his expectation for better performance from its Orlando park. 4. Goldman Sachs analyst Terence Flynn upgraded Ophthotech (OPHT) to Neutral after the stock ended yesterday down 86%. However, he sees a low likelihood that the company's trial testing a Fovista combo with Eylea or Avastin will be positive. 5. Achaogen (AKAO) upgraded to Buy from Hold at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/15/16
JEFF
12/15/16
DOWNGRADE
Target $59
JEFF
Hold
Molina Healthcare downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Molina Healthcare to Hold saying further downside risk for shares is "meaningful" if funding for Medicaid expansion is lowered or eliminated. The analyst lowered his price target for the shares to $59 from $68 and feels the stock's risk/reward is no longer attractive. Windley believes a "lack of clarity on President-elect Trump's healthcare ground rules makes high conviction investing a challenge" in the Managed Care space.
12/13/16
GSCO
12/13/16
UPGRADE
Target $65
GSCO
Buy
Molina Healthcare upgraded to Buy from Neutral at Goldman
Goldman analyst Matthew Borsch upgraded Molina Healthcare to Buy and raised its price target to $65 from $59 citing attractive valuation and believes 2017 results will be more stable and stronger than expectations, particularly if ACA Medicaid coverage is maintained.
01/03/17
PIPR
01/03/17
INITIATION
Target $65
PIPR
Overweight
Molina Healthcare initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Sarah James initiated Molina Healthcare with an Overweight and a $65 price target.
VRTX Vertex
$79.39

0.33 (0.42%)

01/03/17
JANY
01/03/17
NO CHANGE
JANY
Janney sees pricing, rising rates as biotech headwinds in 2017
Janney Capital analyst Debjit Chattopadhyay noted that, on a relative basis vs. the Nasdaq, 2016 was the worst year for the Nasdaq biotechnology index (NBI) since 1994 and he believes the "outlook for 2017 isn't particularly rosy" given structural challenges for the sector along with rising interest rates. He cautions about overenthusiasm on M&A, as Chattopadhyay thinks "cash rich pharma may choose to return cash to shareholders through increased buybacks and dividends," and he believes "M&A, if any, is likely to lead to short-term relief rallies and may not represent a broader turn in sentiment." Meanwhile, broader discussion on healthcare spending and regulatory changes are likely to be bigger drivers of biotech sentiment during 2017 than M&A, said Chattopadhyay, who listed bluebird bio (BLUE), Galapagos NV (GLPG), Vertex (VRTX), Clovis (CLVS) and Nektar (NKTR) as on the firm's 2017 biotechnology focus list.
12/21/16
PIPR
12/21/16
NO CHANGE
Target $129
PIPR
Overweight
Vertex well in lead but Galapagos a competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that while Galapagos NV (GLPG) and AbbVie's (ABBV) CFTR potentiator GLPG1837 is " clearly a competitor" following the Phase II SAPHIRA-1 data, Vertex Pharmaceuticals (VRTX) remains "well in the lead." The Phase III KALYDECO plus follow-on VX-661 data is expected in the first half of 2017 while the Phase II triple combination data with VX-440 and VX-152 is expected in the second half of the year, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Vertex with a $129 price target.
01/09/17
EVER
01/09/17
NO CHANGE
Target $86
EVER
Hold
Vertex guidance for Orkambi, Kalydeco both miss expectations, says Evercore ISI
Evercore ISI analyst John Scotti said Vertex's guidance for FY17 Orkambi revenue of $1.1B-$1.3B is about 17% below sell-side expectations at its midpoint and that the company's forecast for FY17 Kalydeco sales of $690M-$710M is about 5% lower than where Street expectations had been. Scotti has a Hold rating and $86 price target on Vertex shares, which are down about 5% to $75.25 in early pre-market trading.
MDT Medtronic
$73.70

0.83 (1.14%)

01/06/17
DBAB
01/06/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic shares are oversold, says Deutsche Bank
Deutsche Bank analyst Kristen Stewart believes shares of Medtronic are oversold at current levels. The stock is down 20% from its July 2016 high of nearly $89 and have returned to the same level at the time of the close of the Covidien deal in early 2015, Stewart tells investors in a research note. She thinks the current valuation provides investors with an attractive entry point. The analyst reiterates a Buy rating on Medtronic with a $96 price target.
01/03/17
01/03/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Jefferies analyst Randal Konik downgraded Abercrombie & Fitch (ANF) to Hold saying the turnaround continues to struggle at the Abercrombie brand, with no visibility of a turnaround in sight. Also this morning, Oppenheimer analyst Anna Andreeva downgraded Abercrombie & Fitch to Underperform, saying consensus estimates have further downside as the brands "remain in transition amidst increasingly more competitive teen landscape." 2. Oppenheimer analyst Ittai Kidron downgraded Tableau (DATA) to Perform from Outperform to reflect the scope of near-term transition challenges integrating new leadership, the ratable shift, and competition, all hampering near-term upside potential. The analyst also cut Nokia's (NOK) rating to Perform from Outperform. 3. Piper Jaffray analyst Erinn Murphy downgraded Michael Kors (KORS) to Neutral saying the handbag category has been "highly promotional" while inventory levels have been high, particularly at department stores. The analyst sees no positive catalyst in the near-term for shares to re-rate higher and cut her price target for Kors to $48 from $60. 4. JPMorgan analyst Jimmy Bhullar downgraded Voya Financial (VOYA) to Underweight saying the risk/reward skews negative following the stock's outperformance in the second half of 2016. The analyst remains concerned about Voya's "subpar" return-on-equity. 5. JPMorgan analyst Michael Weinstein downgraded Medtronic (MDT) to Neutral saying the new macro environment of rising rates and a strengthening dollar will make it challenging for the shares to outperform in 2017. This morning Weinstein also downgraded Becton Dickinson (BDX) to Neutral saying the new macro environment of rising rates and a strengthening dollar will make it challenging for defensive growth names to outperform in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/17
01/03/17
DOWNGRADE
Target $77

Equal Weight
Medtronic downgraded to Equal Weight on execution issues at Morgan Stanley
As previously reported, Morgan Stanley downgraded Medtronic to Equal Weight from Overweight with a $77 price target. Analyst David Lewis said recent execution issues, decelerating organic growth, and less compelling macro positioning will make 2017 outperformance difficult. Lewis expects currency to remain a headwind and for emerging markets to also be a relative headwind if interest rates rise.
01/03/17
BOFA
01/03/17
DOWNGRADE
BOFA
Neutral
Medtronic downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Medtronic to Neutral and lowered its price target to $78 from $82 saying long-term guidance is too aggressive and near-term organic revenue growth will likely be below 4%.
IONS Ionis Pharmaceuticals
$47.83

0.74 (1.57%)

01/05/17
JANY
01/05/17
NO CHANGE
Target $54
JANY
Neutral
Ionis type 2 diabetes drug efficacy 'middling,' says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Ionis Pharmaceuticals' efficacy for the 50 mg dose of IONIS-GCGR in patients with type 2 diabetes was "middling" and he would rather see the company focus on addressing unmet clinical opportunities in the rare disease setting. Chattopadhyay keeps a Neutral rating and $54 fair value estimate on Ionis.
01/06/17
PIPR
01/06/17
NO CHANGE
Target $56
PIPR
Ionis price target raised to $56 after Novartis pact at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target on Ionis Pharmaceuticals (IONS) to $56 from $51 after the company announced an agreement with Novartis (NVS) to develop and potentially commercialize two investigational antisense therapies that can potentially lower lipoproteins. Schimmer also cites other recent developments, including FDA approval for Spinraza and a competitor setback for revusiran, for his revision. He keeps an Overweight rating on Ionis shares.
01/05/17
JANY
01/05/17
NO CHANGE
Target $44
JANY
Buy
Ionis target lowered to $44 from $54 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay lowered his price target for Ionis Pharmaceuticals to $44 saying this morning's pipeline update conference call was "rather disappointing." The analyst keeps a Neutral rating on the shares.
01/05/17
PIPR
01/05/17
NO CHANGE
PIPR
Overweight
Ionis weakness likely due to DMPK program missing goal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said the weakness this morning in Ionis Pharmaceuticals (IONS) is likely due to the company's disclosure during its pipeline review call that the DMPK program partnered with Biogen (BIIB) didn't quite meet the threshold of biologic activity to advance. However, Ionis indicated it has a new, more potent version and a muscle-lica approach could put the product across the clinical efficacy threshold, he noted. Ionis also gave favorable updates for volanesorsen for elevated triglycerides, IONS-FXIrx for thrombosis and IONS-GCGRrx for diabetes, said Schimmer, who thinks the company has "arguably the most powerful R&D engine in biotech" and keeps his Overweight rating on the shares.
HMSY HMS Holdings
$18.09

-0.31 (-1.68%)

08/18/16
JEFF
08/18/16
DOWNGRADE
Target $23
JEFF
Hold
HMS Holdings downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded HMS Holdings to Hold saying the current valuation fully reflects the company's improved outlook. The analyst raised his price target for the shares to $23 from $19.
11/10/16
BARD
11/10/16
NO CHANGE
Target $23
BARD
Outperform
HMS Holdings selloff overdone, says Baird
Baird analyst Matthew Gillmor said the selloff in HMS Holdings following relatively strong Q3 results is overdone. The analyst said results were ultimately mixed as management talked down 2017 growth but the weakness was more caused by the uncertainty surrounding the durability of the ACA under the Trump administration. With that said, the company's implied risk to EBITDA seems overdone, said Gillmor, who maintained his Outperform rating and lowered his price target to $23 from $24 on HMS Holdings shares.
11/09/16
BARD
11/09/16
NO CHANGE
BARD
HMS Holdings shares defended at Baird
06/01/16
FBCO
06/01/16
INITIATION
Target $19
FBCO
Outperform
HMS Holdings initiated with an Outperform at Credit Suisse
Credit Suisse analyst Robert Willoughby initiated HMS Holdings with an Outperform and $19 price target saying the ongoing mix-shift, coupled with cost-cutting efforts, should drive accelerating EPS growth into 2017.
RDUS Radius Health
$42.44

1.69 (4.15%)

09/21/16
HCWC
09/21/16
NO CHANGE
Target $71
HCWC
Buy
Radius Health price target raised to $71 from $55 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Radius Health to $71 saying results of the second generation transdermal patch in postmenopausal women are promising. ABL-TD patch could not only replace the anabolic drugs on the market, it could expand the market "significantly," Werther tells investors in a research note. She keeps a Buy rating on Radius.
12/09/16
MAXM
12/09/16
NO CHANGE
MAXM
Sell
Radius Health data on RAD1901 disappointing, says Maxim
Maxim analyst Jason McCarthy called the newly announced data from Radius Health on a phase 1b study of RAD1901 in breast cancer "disappointing," saying early data from phase I studies suggests that the drug shows a lack of efficacy in the difficult to treat population it is targeting. McCarthy, who continues to believe Radius is overvalued, maintains a Sell rating on the stock.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
12/08/16
CANT
12/08/16
NO CHANGE
Target $70
CANT
Buy
Radius RAD1901 data positive, but below expectations, says Cantor
Cantor Fitzgerald analyst Mara Goldstein said the Phase I data on RAD1901 was positive and "well-received" by clinicians at the San Antonio Breast Cancer Symposium where it was presented. However, she attributes the pullback in the stock to an expectation for greater responses. Goldstein, who continues to see value in this program and thinks that RAD1901 has the "makings of a commercial drug," keeps a Buy rating and $70 price target on Radius Health shares.
ACOR Acorda Therapeutics
$21.15

0.4 (1.93%)

11/30/16
JPMS
11/30/16
UPGRADE
JPMS
Overweight
Acorda Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Acorda Therapeutics to Overweight from Not rated and Neutral prior to the restriction. The analyst said upcoming Phase 3 data for CVT-301 and a decision in the pending Ampyra IP cases have the potential to act as catalysts.
12/15/16
CANT
12/15/16
INITIATION
CANT
Neutral
Acorda Therapeutics initiated with a Neutral at Cantor
01/03/17
RAJA
01/03/17
NO CHANGE
RAJA
Drug price hikes continue unabated, says Raymond James
In a research note titled "Think the Era of Drug Price Increases is Over? Think Again.," Raymond James analyst Christopher Raymond says drug price increases in 2017 are continuing unabated. According to Wolters Kluwer Health, January 1 saw a "sizeable amount of key biotech drug price increases," Raymond tells investors. The price hikes look in-line with previous patterns, or - in the case of Biogen (BIIB) - "measurably more aggressive than norm," the analyst contends. Of the names he follows, Biogen, Acorda Therapeutics (ACOR) and AMAG Pharmaceuticals (AMAG) implemented increases. Raymond also highlights AstraZeneca's (AZN) 5% Lynparza increase and Roche's (RHHBY) "slew of increases" with Actemra up 1.5%, Herceptin up 3%, Pegasys up 5%.
12/19/16
JANY
12/19/16
INITIATION
Target $23
JANY
Neutral
Acorda Therapeutics initiated with a Neutral at Janney Capital
Janney Capital analyst Ken Trbovich with a Neutral and a $23 price target.
IRWD Ironwood
$15.85

0.42 (2.72%)

12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.
04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
AGN Allergan
$220.62

1.54 (0.70%)

12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
01/05/17
WELS
01/05/17
NO CHANGE
WELS
Outperform
Allergan 2017 outlook in-line with estimates, says Wells Fargo
Wells Fargo analyst David Maris says Allergan's preliminary outlook for 2017 today was in-line with his and the current expectations. The analyst notes Allergan's outlook does not include accretion from the recently announced acquisition of LifeCell. Maris keeps an Outperform rating on the shares with a $250-$255 price target range.
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.
ASND Ascendis Pharma
$20.68

0.01 (0.05%)

09/26/16
WEDB
09/26/16
INITIATION
Target $34
WEDB
Outperform
Ascendis Pharma initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started Ascendis Pharma with an Outperform rating and $34 price target. The company's TransCon technology platform creates unique sustained-release prodrug candidates that "reduce treatment burden and regulatory hurdles while retaining composition-of-matter IP," Moussatos tells investors in a research note.
NUVA NuVasive
$67.14

0.37 (0.55%)

12/29/16
PIPR
12/29/16
NO CHANGE
PIPR
Overweight
Piper sees NuVasive shares pushing higher in 2017
Piper Jaffray analyst Matt O'Brien views NuVasive's XLIF approval in Japan as a "net positive development" given management's expectations for approval in December. He believes the company will regain all of its XLIF share put on pause during the reclassification. The analyst continues to expect "strong" earnings and sales results "this year and in the years to come," which he thinks should continue to push NuVasive shares higher in 2017. O'Brien has an Overweight rating on the name with a $70 price target.
12/27/16
PIPR
12/27/16
NO CHANGE
PIPR
Piper sees sales hiring spike at K2M Group
Piper Jaffray analyst Matt O'Brien says K2M Group's (KTWO) job postings for sales reps have "risen meaningfully" in the past three months, which he views as a sign of confidence heading into 2017. In addition, NuVasive's (NUVA) job postings for sales reps have risen throughout the course of the year, O'Brien tells investors in a research note. The analyst continues to believe investors can own all of the pure-play spine players, but he prefers K2M slightly over NuVasive.
12/09/16
LEER
12/09/16
NO CHANGE
Target $80
LEER
Outperform
NuVasive price target raised to $80 from $73 at Leerink
Leerink analyst Richard Newitter raised his price target for NuVasive to $80 from $73 saying that a number of momentum drivers heading into 2017 increase his confidence that the company should meet or exceed his 12.6% growth forecast. The analyst reiterates an Outperform rating on the shares.
01/09/17
PIPR
01/09/17
NO CHANGE
Target $70
PIPR
Overweight
NuVasive preannounced 'solid' Q4 results, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says NuVasive this morning preannounced "solid" Q4 results and provided 2017 guidance in-line with expectations. Momentum in the business remains "robust," O'Brien tells investors in a research note. He points out that his end of the year checks for next year were positive across the board. The analyst thinks investors should be accumulating shares of NuVasive. He keeps an Overweight rating on the name with a $70 price target.
SCAI Surgical Care Affiliates
$48.75

1.7 (3.61%)

01/04/17
SBSH
01/04/17
INITIATION
Target $50
SBSH
Neutral
Surgical Care Affiliates initiated with a Neutral at Citi
Citi analyst Ralph Giacobbe started Surgical Care Affiliates with a Neutral rating and $50 price target.
09/22/16
RHCO
09/22/16
NO CHANGE
RHCO
Surgical Care Affiliates fundamentals 'compelling,' says SunTrust
After meeting with Surgical Care's management, SunTrust analyst David Macdonald says that the company has "strong core trends, industry tailwinds, robust growth/investment opportunities and robust free cash flow." He says that the company's pipeline is strong, while the company should continue to benefit from multiple trends in the healthcare sector. He keeps a Buy rating on the stock.
06/22/16
GSCO
06/22/16
DOWNGRADE
Target $48
GSCO
Neutral
Surgical Care Affiliates downgraded to Neutral from Buy at Goldman
Goldman analyst Matthew Borsch downgraded Surgical Care Affiliates to Neutral citing valuation and maintained its $48 price target.
NH NantHealth
$10.56

0.29 (2.82%)

06/27/16
ADAM
06/27/16
INITIATION
Target $17
ADAM
Buy
NantHealth initiated with a Buy at Canaccord
Canaccord analyst Richard Close initiated NantHealth with a Buy and $17 price target following its recent IPO. The firm sees NantHealth as a leader in precision medicine, bringing to market an innovative cancer diagnostic test coupled with a cloud-based offering to drive increased value.
06/27/16
FANA
06/27/16
INITIATION
Target $18
FANA
Overweight
NantHealth initiated with an Overweight at First Analysis
First Analysis analyst Joseph Munda started NantHealth with an Overweight rating and $18 price target, saying he believes the company has assembled a powerful combination of information technology and advanced molecular diagnostics and views its leadership as exceptionally well qualified.
01/05/17
CANT
01/05/17
INITIATION
Target $17
CANT
Overweight
NantHealth initiated with an Overweight at Cantor
Cantor analyst Steven Halper initiated NantHealth with an Overweight and a $17 price target.
06/27/16
06/27/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Spectra Energy (SE) initiated with an Outperform at RBC Capital by analyst Elvira Scotto, who has a $39 price target on the stock. The analyst believes Spectra can deliver solid, highly visible cash-flow and dividend growth over the next several years underpinned by a robust backlog of demand-pull growth projects. 2. GW Pharmaceuticals (GWPH) initiated with a Sell at Janney Capital by analyst Ken Trbovich, who has a $40 price target on the stock. The analyst said GW awaits imminent results of Phase 3 trial results in Lennox-Gastaut Syndrome. Unfortunately, even if the data in LGS is good, Trbovich thinks its valuation exceeds the commercial prospects for drugs that treat orphan epilepsy indications.3. NantHealth (NH) initiated with a Buy at Canaccord by analyst Richard Close, who has a $17 price target following its recent IPO. The firm sees NantHealth as a leader in precision medicine, bringing to market an innovative cancer diagnostic test coupled with a cloud-based offering to drive increased value. NantHealth was also initiated with an Outperform at FBR Capital and Cowen and an Ovweight at First Analysis, with analyst Joseph Munda saying he believes the company has assembled a powerful combination of information technology and advanced molecular diagnostics and views its leadership as exceptionally well qualified. 4. Skyworks (SWKS) initiated with an Underweight at Morgan Stanley by analysts led by Craig Hettenbach, who put a $61 price target on the stock. The analyst said Skyworks is far behind Broadcom on business diversification and customer concentration will likely pressure the stock's multiple. 5. Clearside Biomedical (CLSD) initiated with an Outperform at Cowen by analyst Boris Peaker, who noted the company is developing a novel device that enables the administration of drugs to the back of the eye with minimal front of the eye exposure which can be used for indications like AMD, DME, and glaucoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ARIA ARIAD
$13.74

0.34 (2.54%)

10/26/16
JEFF
10/26/16
NO CHANGE
Target $11
JEFF
Buy
ARIAD price target lowered to $11 from $13 at Jefferies
Jefferies analyst Eun Yang lowered her price target for ARIAD Pharmaceuticals to $11 following the recent scrutiny on Iclusig pricing. Iclusig's pricing scheme "has been overly aggressive," but there is a "clear therapeutic value" to the drug, Yang tells investors in a research note. She believes the company will likely need to modify its pricing strategy. Yang lowered her sales estimates by 23% in 2017 and beyond but keeps a Buy rating on ARIAD. William Blair this morning raised its price target for the shares to $15 from $12.
11/03/16
DBAB
11/03/16
INITIATION
Target $9.5
DBAB
Hold
ARIAD initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Andrew Peters started ARIAD Pharmaceuticals with a Hold rating and $9.50 price target. Headline risk from pricing could overshadow any positive pipeline news flow until the issue is resolved, Peters tells investors in a research note. He expects the stock to be range-bound in the near-term.
11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.
BIIB Biogen
$295.00

1.43 (0.49%)

12/28/16
RAJA
12/28/16
NO CHANGE
Target $386
RAJA
Strong Buy
Biogen price target raised to $386 from $375 at Raymond James
Raymond James analyst Christopher Raymond raised Biogen's price target to $386 from $375 following the release of Spinraza pricing. Raymond continues to believe the Spinraza launch could provide strong momentum for Biogen shares in 2017 and reiterates his Strong Buy rating.
12/27/16
STFL
12/27/16
NO CHANGE
Target $65
STFL
Hold
Spinraza launch could pose risk AveXis enrollment timelines, says Stifel
Stifel analyst Katherine Breedis noted that Biogen (BIIB) and partner Ionis (IONS) announced receipt of FDA approval of Spinraza for treatment of all types of Spinal Muscular Atrophy, or SMA, in-line with her expectations for a late 2016 or early 2017 U.S. approval with a "broad label." She anticipates it will garner rapid uptake as it becomes commercially available and believes Spinraza may be on the market as much as 6 months prior to the start of enrollment of AveXis' (AVXS) pivotal study of AVXS-101 in SMA Type 1 and the Phase 1 study of AVXS-101 in SMA Type 2, which could present risk to their enrollment timelines, she tells investors. Breedis maintains a Hold rating and $65 price target on Avexis shares, which are down about 6% to $50 in pre-market trading after its competitors approval news.

TODAY'S FREE FLY STORIES

DIS

Disney

$112.14

-0.1 (-0.09%)

, LGF.A

Lionsgate

$26.08

0.76 (3.00%)

16:26
03/26/17
03/26
16:26
03/26/17
16:26
Hot Stocks
Box Office Battle: 'Beauty And The Beast' fights off 'Power Rangers' »

Disney's (DIS)…

DIS

Disney

$112.14

-0.1 (-0.09%)

LGF.A

Lionsgate

$26.08

0.76 (3.00%)

LGF.B

Lionsgate

$23.93

0.6 (2.57%)

TWX

Time Warner

$97.51

0.33 (0.34%)

SNE

Sony

$32.21

0.43 (1.35%)

FOX

21st Century Fox

$30.88

0.13 (0.42%)

FOXA

21st Century Fox

$31.52

0.19 (0.61%)

CMCSA

Comcast

$37.38

0.16 (0.43%)

CMCSK

Comcast

VIA

Viacom

$44.50

0.1 (0.23%)

VIAB

Viacom

$43.06

0.1 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 03

    May

  • 04

    May

  • 25

    May

TSLA

Tesla

$263.16

8.38 (3.29%)

15:52
03/26/17
03/26
15:52
03/26/17
15:52
Hot Stocks
Tesla CEO: High performance Model 3 'probably a year from now' »

Asked by a Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

TSLA

Tesla

$263.16

8.38 (3.29%)

15:47
03/26/17
03/26
15:47
03/26/17
15:47
Hot Stocks
Tesla CEO showcases 'release candidate version' of Model 3 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

TSLA

Tesla

$263.16

8.38 (3.29%)

15:44
03/26/17
03/26
15:44
03/26/17
15:44
Hot Stocks
Tesla CEO: Minimizing configuration complexity for early Model 3 vehicles »

Asked by a Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

TSLA

Tesla

$263.16

8.38 (3.29%)

15:42
03/26/17
03/26
15:42
03/26/17
15:42
Hot Stocks
Tesla CEO: Next generation Roadster 'few years away' »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

AAL

American Airlines

$41.73

0.32 (0.77%)

, ZNH

China Southern Airlines

$35.13

0.99 (2.90%)

15:34
03/26/17
03/26
15:34
03/26/17
15:34
Hot Stocks
China Southern negotiating 'major strategic cooperation' with American Airlines »

China Southern Airlines…

AAL

American Airlines

$41.73

0.32 (0.77%)

ZNH

China Southern Airlines

$35.13

0.99 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

AMZN

Amazon.com

$845.61

-1.77 (-0.21%)

, AAPL

Apple

$140.64

-0.28 (-0.20%)

15:22
03/26/17
03/26
15:22
03/26/17
15:22
Periodicals
Amazon explores 'ambitious collection' of retail concepts, NY Times says »

Amazon (AMZN) has an…

AMZN

Amazon.com

$845.61

-1.77 (-0.21%)

AAPL

Apple

$140.64

-0.28 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 16

    May

MGI

MoneyGram

$16.66

0.03 (0.18%)

, EEFT

Euronet

$83.54

0.15 (0.18%)

14:39
03/26/17
03/26
14:39
03/26/17
14:39
Hot Stocks
MoneyGram enters confidentiality agreement with Euronet »

MoneyGram (MGI) announced…

MGI

MoneyGram

$16.66

0.03 (0.18%)

EEFT

Euronet

$83.54

0.15 (0.18%)

BABA

Alibaba

$108.04

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

OMAM

OM Asset Management

$14.56

0.13 (0.90%)

, ODMTY

Old Mutual

14:33
03/26/17
03/26
14:33
03/26/17
14:33
Hot Stocks
OM Asset Management says Old Mutual to sell 24.95% stake »

OM Asset Management…

OMAM

OM Asset Management

$14.56

0.13 (0.90%)

ODMTY

Old Mutual

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$61.32

-0.09 (-0.15%)

14:20
03/26/17
03/26
14:20
03/26/17
14:20
Hot Stocks
Copart announces 2-for-1 stock split »

Copart announced Friday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$11.41

0.03 (0.26%)

14:17
03/26/17
03/26
14:17
03/26/17
14:17
Hot Stocks
BRF S.A. says takes action in response to Brazil meat scandal »

BRF S.A. issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$28.43

1.96 (7.40%)

14:00
03/26/17
03/26
14:00
03/26/17
14:00
Periodicals
Micron could move higher, CEO doesn't see supply glut, Barron's says »

Micron could continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Apr

GME

GameStop

$20.70

-3.26 (-13.61%)

13:52
03/26/17
03/26
13:52
03/26/17
13:52
Periodicals
GameStop 'still has strengths,' Barron's says »

GameStop "still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YHOO

Yahoo

$46.40

-0.2 (-0.43%)

, VZ

Verizon

$49.68

0.04 (0.08%)

13:41
03/26/17
03/26
13:41
03/26/17
13:41
Periodicals
Yahoo liquidation could generate 20% gain, Barron's says »

Shares of Yahoo (YHOO)…

YHOO

Yahoo

$46.40

-0.2 (-0.43%)

VZ

Verizon

$49.68

0.04 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BABA

Alibaba

$108.04

-0.21 (-0.19%)

, TCEHY

Tencent

$29.02

0.15 (0.52%)

13:36
03/26/17
03/26
13:36
03/26/17
13:36
Periodicals
Alibaba, Tencent could see boost from fintech growth, Barron's says »

Alibaba (BABA) and…

BABA

Alibaba

$108.04

-0.21 (-0.19%)

TCEHY

Tencent

$29.02

0.15 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$49.73

-0.03 (-0.06%)

13:34
03/26/17
03/26
13:34
03/26/17
13:34
Periodicals
Total could 'find favor with investors,' Barron's says »

Total "could again…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPG

Simon Property

$167.95

0.39 (0.23%)

, MAC

Macerich

$63.87

0.39 (0.61%)

13:13
03/26/17
03/26
13:13
03/26/17
13:13
Periodicals
Mall REITs potentially 'the next nightmare,' Barron's says »

Barron's questions…

SPG

Simon Property

$167.95

0.39 (0.23%)

MAC

Macerich

$63.87

0.39 (0.61%)

TCO

Taubman Centers

$65.03

0.02 (0.03%)

SKT

Tanger Factory

$32.51

0.26 (0.81%)

CBL

CBL & Associates

$9.45

0.31 (3.39%)

SRG

Seritage Growth Properties

$43.51

1.25 (2.96%)

SHLD

Sears

$8.50

0.31 (3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 28

    Apr

  • 02

    May

  • 04

    May

  • 20

    Jun

SIVB

SVB Financial

$177.94

-0.24 (-0.13%)

12:56
03/26/17
03/26
12:56
03/26/17
12:56
Periodicals
SVB Financial could gain 25% in a year, Barron's says »

SVB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$13.70

-0.1 (-0.72%)

12:36
03/26/17
03/26
12:36
03/26/17
12:36
Periodicals
SolarEdge could rise 40% or more in a year, Barron's says »

SolarEdge shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$44.50

0.1 (0.23%)

, VIAB

Viacom

$43.06

0.1 (0.23%)

12:25
03/26/17
03/26
12:25
03/26/17
12:25
Periodicals
Viacom could gain 40% in a year, Barron's says »

Viacom is "tracking…

VIA

Viacom

$44.50

0.1 (0.23%)

VIAB

Viacom

$43.06

0.1 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    May

GIII

G-III Apparel

$22.92

-0.04 (-0.17%)

20:25
03/24/17
03/24
20:25
03/24/17
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

FOX

21st Century Fox

$30.88

0.13 (0.42%)

, FOXA

21st Century Fox

$31.52

0.19 (0.61%)

18:47
03/24/17
03/24
18:47
03/24/17
18:47
Periodicals
21st Century Fox, Sky deal to be weighed by EU regulators, Bloomberg says »

21st Century Fox's…

FOX

21st Century Fox

$30.88

0.13 (0.42%)

FOXA

21st Century Fox

$31.52

0.19 (0.61%)

SKYAY

Sky

$48.36

-0.826 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

UPS

UPS

$105.05

-0.6 (-0.57%)

18:19
03/24/17
03/24
18:19
03/24/17
18:19
Periodicals
UPS found liable for illegally shipping untaxed cigarettes in NY, Reuters says »

U.S. District Judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 30

    Mar

TCBI

Texas Capital

$80.25

0.3 (0.38%)

, ENH

Endurance Specialty

$92.97

0.1 (0.11%)

18:13
03/24/17
03/24
18:13
03/24/17
18:13
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

TCBI

Texas Capital

$80.25

0.3 (0.38%)

ENH

Endurance Specialty

$92.97

0.1 (0.11%)

DSW

DSW

$19.27

0.13 (0.68%)

WETF

WisdomTree

$8.59

0.03 (0.35%)

SCAI

Surgical Care Affiliates

MIK

Michaels

$21.96

0.17 (0.78%)

UNH

UnitedHealth

$165.00

-0.29 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

AAPL

Apple

$140.64

-0.28 (-0.20%)

17:42
03/24/17
03/24
17:42
03/24/17
17:42
Periodicals
Apple can make new highs on iPhone 8 launch, dividend hike, Barron's says »

Apple's share price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.